Nothing Special   »   [go: up one dir, main page]

ATE528396T1 - Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften - Google Patents

Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften

Info

Publication number
ATE528396T1
ATE528396T1 AT05809866T AT05809866T ATE528396T1 AT E528396 T1 ATE528396 T1 AT E528396T1 AT 05809866 T AT05809866 T AT 05809866T AT 05809866 T AT05809866 T AT 05809866T AT E528396 T1 ATE528396 T1 AT E528396T1
Authority
AT
Austria
Prior art keywords
polypeptide
amino acids
mutagenesis
libraries
look
Prior art date
Application number
AT05809866T
Other languages
English (en)
Inventor
Roberto Crea
Original Assignee
Bioren Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioren Inc filed Critical Bioren Inc
Application granted granted Critical
Publication of ATE528396T1 publication Critical patent/ATE528396T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1093General methods of preparing gene libraries, not provided for in other subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • G01N33/6857Antibody fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT05809866T 2004-07-06 2005-07-06 Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften ATE528396T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58591804P 2004-07-06 2004-07-06
PCT/US2005/024140 WO2006023144A2 (en) 2004-07-06 2005-07-06 Look-through mutagenesis for developing altered polypeptides with enhanced properties

Publications (1)

Publication Number Publication Date
ATE528396T1 true ATE528396T1 (de) 2011-10-15

Family

ID=35968026

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05809866T ATE528396T1 (de) 2004-07-06 2005-07-06 Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften

Country Status (9)

Country Link
US (1) US9012369B2 (de)
EP (1) EP1774019B1 (de)
JP (2) JP4939410B2 (de)
AT (1) ATE528396T1 (de)
BR (1) BRPI0513155B1 (de)
CA (1) CA2572917C (de)
ES (1) ES2372503T3 (de)
MX (1) MX2007000105A (de)
WO (1) WO2006023144A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2006381B1 (de) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmakokinetik von antikörpern
EP2012829A4 (de) * 2006-04-24 2010-04-21 Protelix Inc Verfahren zur herstellung eines viralen impfstoffes und therapeutischer peptid-antigene
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EP2118281A2 (de) 2007-02-12 2009-11-18 Codexis, Inc. Struktur-wirkungs-beziehungen
EP2392653B1 (de) * 2007-07-12 2014-03-19 New England Biolabs, Inc. Restriktionsendonukleasen mit hoher Fidelität
JP5566108B2 (ja) * 2007-09-26 2014-08-06 中外製薬株式会社 抗il−6レセプター抗体
EP4339294A3 (de) 2007-09-26 2024-10-16 Chugai Seiyaku Kabushiki Kaisha Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers durch aminosäuresubstitution in cdr
MY163473A (en) 2007-09-26 2017-09-15 Chugai Pharmaceutical Co Ltd Modified antibody constant region
US20110189203A1 (en) 2007-11-27 2011-08-04 Ablynx N.V. Immunoglobulin constructs
US20110118447A1 (en) * 2007-12-31 2011-05-19 Xoma Technology Ltd. Methods and materials for targeted affinity enhancement
KR20240113501A (ko) 2008-04-11 2024-07-22 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
CA2723277A1 (en) 2008-05-02 2009-11-05 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
WO2010111707A1 (en) 2009-03-27 2010-09-30 Sapphire Energy, Inc. Variant isoprenoid producing enzymes and uses thereof
US10618964B2 (en) 2009-04-10 2020-04-14 Ablynx N.V. Nanobody against IL-6R
KR20130119990A (ko) 2009-04-10 2013-11-01 아블린쓰 엔.브이. Il-6r에 대한 개선된 아미노산 서열 및 il-6r 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드
CA2764398A1 (en) 2009-06-05 2010-12-09 Erik Depla Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
EP3248987A1 (de) 2010-07-30 2017-11-29 Novartis AG Fibronectin-cradle-moleküle und bibliotheken
EP2619226B1 (de) * 2010-09-22 2018-09-12 Amgen Inc. Träger-immunglobuline und verwendungen davon
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
AU2012311443B2 (en) 2011-09-23 2016-12-01 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
ES2819075T3 (es) 2011-10-11 2021-04-14 Viela Bio Inc Matrices de soporte derivadas de TN3 específicas para CD40L y sus métodos de empleo
CN113416256A (zh) 2011-11-30 2021-09-21 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
KR20140132748A (ko) 2012-03-02 2014-11-18 아블린쓰 엔.브이. 슈도모나스 애루기노사 pcrv 결합 단일 가변 도메인 항체
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
US10309969B2 (en) * 2013-01-24 2019-06-04 Abtlas Co., Ltd. Protein combination-based FV library, and preparation method therefor
EP2989202B1 (de) 2013-04-25 2019-04-10 Sutro Biopharma, Inc. Die verwendung des lambda-gam proteins in der ribosomen-display-technologie
EP2989239B1 (de) * 2013-04-25 2018-07-04 Sutro Biopharma, Inc. Auswahl von fab-fragmenten anhand von ribosomaler display-technik
JP6442404B2 (ja) 2013-06-11 2018-12-19 国立研究開発法人国立精神・神経医療研究センター 再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法
US9409139B2 (en) 2013-08-05 2016-08-09 Twist Bioscience Corporation De novo synthesized gene libraries
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
JP2017534617A (ja) 2014-10-21 2017-11-24 アブリンクス エン.ヴェー. Il−6r関連疾患の処置
CA2975852A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
SG11201705093UA (en) 2015-02-27 2017-07-28 Chugai Pharmaceutical Co Ltd Composition for treating il-6-related diseases
KR20240093725A (ko) 2015-03-12 2024-06-24 메디뮨 엘엘씨 알부민 융합 단백질의 정제 방법
WO2016172377A1 (en) 2015-04-21 2016-10-27 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
PL3299810T3 (pl) 2015-05-19 2021-12-13 National Center Of Neurology And Psychiatry Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm)
ES2881683T3 (es) 2015-05-21 2021-11-30 Full Spectrum Genetics Inc Procedimiento para mejorar las características de las proteínas
CA2998169A1 (en) * 2015-09-18 2017-03-23 Twist Bioscience Corporation Oligonucleic acid variant libraries and synthesis thereof
CN108698012A (zh) 2015-09-22 2018-10-23 特韦斯特生物科学公司 用于核酸合成的柔性基底
CN108603307A (zh) 2015-12-01 2018-09-28 特韦斯特生物科学公司 功能化表面及其制备
USD782516S1 (en) 2016-01-19 2017-03-28 Apple Inc. Display screen or portion thereof with graphical user interface
EP3500672A4 (de) 2016-08-22 2020-05-20 Twist Bioscience Corporation De-novo-synthetisierte nukleinsäure-bibliotheken
JP6871364B2 (ja) 2016-09-21 2021-05-12 ツイスト バイオサイエンス コーポレーション 核酸に基づくデータ保存
CA3047128A1 (en) 2016-12-16 2018-06-21 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
CA3054303A1 (en) 2017-02-22 2018-08-30 Twist Bioscience Corporation Nucleic acid based data storage
WO2018170169A1 (en) 2017-03-15 2018-09-20 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
WO2018231872A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2019051501A1 (en) 2017-09-11 2019-03-14 Twist Bioscience Corporation PROTEINS BINDING TO GPCR AND METHODS OF SYNTHESIS
EP3698808A4 (de) 2017-10-20 2021-07-14 Hyogo College Of Medicine Anti-il-6 rezeptorantikörper enthaltende medizinische zusammensetzung zur verhinderung von postoperativer adhäsion
KR102637566B1 (ko) 2017-10-20 2024-02-16 트위스트 바이오사이언스 코포레이션 폴리뉴클레오타이드 합성을 위한 가열된 나노웰
US10936953B2 (en) 2018-01-04 2021-03-02 Twist Bioscience Corporation DNA-based digital information storage with sidewall electrodes
KR20210013128A (ko) 2018-05-18 2021-02-03 트위스트 바이오사이언스 코포레이션 핵산 하이브리드화를 위한 폴리뉴클레오타이드, 시약 및 방법
AU2020229349A1 (en) 2019-02-26 2021-10-14 Twist Bioscience Corporation Variant nucleic acid libraries for GLP1 receptor
CA3131691A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
EP3987019A4 (de) 2019-06-21 2023-04-19 Twist Bioscience Corporation Barcode-basierte nukleinsäuresequenzanordnung
EP4034566A4 (de) 2019-09-23 2024-01-24 Twist Bioscience Corporation Variante nukleinsäurebibliotheken für crth2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2078518T3 (es) 1990-04-05 1995-12-16 Roberto Crea Mutagenesis por desplazamiento completo.
EP1230269A2 (de) 1999-11-03 2002-08-14 Maxygen, Inc. Erzeugung von antikörperdiversität
AU784983B2 (en) * 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
ES2328345T3 (es) * 2002-04-17 2009-11-12 Bioren, Inc. Bibliotecas universales para inmunoglobulinas.
ATE374255T1 (de) * 2002-04-17 2007-10-15 Bioren Inc Doping bei der walk-through-mutagenese
KR20060034650A (ko) * 2003-06-27 2006-04-24 바이오렌 인코포레이티드 룩-스루 돌연변이

Also Published As

Publication number Publication date
EP1774019A2 (de) 2007-04-18
ES2372503T3 (es) 2012-01-20
CA2572917C (en) 2012-04-03
BRPI0513155B1 (pt) 2021-07-20
US9012369B2 (en) 2015-04-21
CA2572917A1 (en) 2006-03-02
BRPI0513155A (pt) 2008-04-29
JP2012041347A (ja) 2012-03-01
US20080214406A1 (en) 2008-09-04
JP2008505642A (ja) 2008-02-28
EP1774019B1 (de) 2011-10-12
JP4939410B2 (ja) 2012-05-23
WO2006023144A2 (en) 2006-03-02
EP1774019A4 (de) 2009-05-20
WO2006023144A3 (en) 2006-08-17
MX2007000105A (es) 2007-07-18

Similar Documents

Publication Publication Date Title
ATE528396T1 (de) Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften
WO2005003345A3 (en) Look-through mutagenesis
ES2078518T3 (es) Mutagenesis por desplazamiento completo.
Camporeale et al. K8 and K12 are biotinylated in human histone H4
Tu et al. Sequence analysis and molecular docking of antithrombotic peptides from casein hydrolysate by trypsin digestion
Ma et al. Differential proteomic analysis of platelets suggested possible signal cascades network in platelets treated with salvianolic acid B
Lai et al. The emerging role of the peptidome in biomarker discovery and degradome profiling
Schroeter et al. Bone protein “extractomics”: comparing the efficiency of bone protein extractions of Gallus gallus in tandem mass spectrometry, with an eye towards paleoproteomics
ATE344456T1 (de) Durch affinität ausgewählte unterschriftspeptide zur identifizierung und quantifizierung von proteinen
DE60139326D1 (de) Detektion von peptiden
BR0112119A (pt) Polipeptìdeo isolado, molécula de ácido nucléico isolado, vetor, célula hospedeira recombinante, método de produzir a proteìna zcyto21, anticorpo ou fragmento de anticorpo, método de detectar a presença da expressão do gene zcyto21 em uma amostra biológica
WO2002042427A3 (en) Mass tags for quantitative analysis
Slagboom et al. Analytical strategies in venomics
DE60109490D1 (de) Umgekehrtes labelierungsverfahren zur schnellen identifikation von marker/ziel-proteinen
CN105277712B (zh) 一种鉴定赖氨酸ε‑氨基侧链单甲基化修饰的方法
JP2019507341A5 (de)
Fu et al. rMCP-2, the major rat mucosal mast cell protease, an analysis of its extended cleavage specificity and its potential role in regulating intestinal permeability by the cleavage of cell adhesion and junction proteins
ES2079621T3 (es) Procedimiento de identificacion o de titulacion de proteinas y aplicaciones.
Zoumaro-Djayoon et al. Targeted analysis of tyrosine phosphorylation by immuno-affinity enrichment of tyrosine phosphorylated peptides prior to mass spectrometric analysis
DE69902924D1 (de) Neue methoden zum auffinden von liganden- und ziel-biomolekülen
ATE288589T1 (de) Verfahren zur analyse von proteinen
SE0302559D0 (sv) Method
WO2008142664A3 (en) Exposed thymidine kinase 1 peptides, ligands and methods employing the same
WO2005005990A3 (en) Inverse labeling method for the rapid identification of marker target proteins
Jiang et al. Investigating the loss of major yolk proteins during the processing of sea cucumber (Apostichopus japonicus) using an MRM-based targeted proteomics strategy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties